BRTX · BioRestorative Therapies, Inc.

Summary

BioRestorative Therapies, Inc. commenced a public offering on February 11, 2026, of 12,560,715 Common Units and 1,725,000 Pre-Funded Units at $0.35 and $0.3499 per unit, respectively, which closed on February 13, 2026, generating approximately $5.0 million in gross proceeds. The Company entered into a Securities Purchase Agreement and Placement Agency Agreement with Rodman & Renshaw LLC, imposing 90-day and 9-month issuance restrictions.

Key takeaways

• Commenced offering February 11, 2026: 12,560,715 Common Units ($0.35/unit) + 1,725,000 Pre-Funded Units ($0.3499/unit)
• Closed offering February 13, 2026; gross proceeds $5.0 million
• Common Stock Warrants: exercise $0.35/share, 5-year term, immediately exercisable
• Pre-Funded Warrants: exercise $0.0001/share, exercisable until fully exercised
• Placement Agent Warrants: 350,000 shares at $0.4375/share (125% of offering price)
• Net proceeds for BRTX-100 clinical trials, ThermoStem R&D, biocosmeceuticals, working capital